NGM Biopharmaceuticals, Inc.

NASDAQ:NGM

1.54 (USD) • At close April 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 0.1650.5821.4232.24718.1817.9118.29320.94820.95918.57516.77321.57519.76723.48219.75524.36431.08321.56825.34125.55247.11920.81522.11818.613
Cost of Revenue 0.5180.51.1191.1191.1141.0921.400000000000000000
Gross Profit -0.3530.0820.3041.12817.0676.8196.89320.94820.95918.57516.77321.57519.76723.48219.75524.36431.08321.56825.34125.55247.11920.81522.11818.613
Gross Profit Ratio -2.1390.1410.2140.5020.9390.8620.83111111111111111111
Reseach & Development Expenses 21.37222.94232.35140.85746.72246.10645.43342.80638.72938.71443.5740.69940.0646.97938.49438.43941.95428.95328.81929.52728.94124.47322.84619.454
General & Administrative Expenses 7.9388.6719.64711.5849.75610.1099.92710.7239.4548.8679.8238.7217.386.466.7946.5956.4235.6126.2295.3675.1224.8113.4583.874
Selling & Marketing Expenses 000000000000000000000000
SG&A 7.9388.6719.64711.5849.75610.1099.92710.7239.4548.8679.8238.7217.386.466.7946.5956.4235.6126.2295.3675.1224.8113.4583.874
Other Expenses -0.048-0.015-0.134-0.037-0.170.0780.005-0.045-0.0950.035-0.1870.187-0.434-0.068-0.4710.38-0.2010.096-0.006-0.0360.096-0.0140.0950.022
Operating Expenses 29.3131.61341.99852.44156.47856.21555.3653.52948.18347.58153.39349.4247.4453.43945.28845.03448.37734.56535.04834.89434.06329.28426.30423.328
Operating Income -29.663-31.031-40.575-50.194-38.297-48.304-47.067-32.581-27.224-29.006-36.62-27.845-27.673-29.957-25.533-20.67-17.294-12.997-9.707-9.34213.056-8.469-4.186-4.715
Operating Income Ratio -179.776-53.318-28.514-22.338-2.106-6.106-5.676-1.555-1.299-1.562-2.183-1.291-1.4-1.276-1.292-0.848-0.556-0.603-0.383-0.3660.277-0.407-0.189-0.253
Total Other Income Expenses Net 1.993-0.015-0.1342.5471.861.0430.5480.131-0.0950.035-0.1870.187-0.434-0.068-0.4710.38-0.2010.096-0.006-0.0360.096-0.0140.0950.022
Income Before Tax -27.67-28.797-38.261-47.647-36.437-47.261-46.519-32.45-27.234-28.865-36.692-27.544-27.991-29.765-25.616-19.115-15.941-10.917-7.669-8.26814.165-7.517-3.2-3.941
Income Before Tax Ratio -167.697-49.479-26.888-21.205-2.004-5.974-5.609-1.549-1.299-1.554-2.188-1.277-1.416-1.268-1.297-0.785-0.513-0.506-0.303-0.3240.301-0.361-0.145-0.212
Income Tax Expense 7.244-2.249-2.448-2.547-1.86-1.043-0.548-0.131-27.234-0.106-0.115-0.114-1.669-0.26-0.388-1.175-3.321-1.984-2.044-1.11-1.013-0.966-0.891-0.752
Net Income -27.67-28.797-38.261-45.1-34.577-46.218-45.971-32.319-27.234-28.865-36.692-27.544-27.991-29.765-25.616-19.115-15.941-10.917-7.669-8.26814.165-7.517-3.2-3.941
Net Income Ratio -167.697-49.479-26.888-20.071-1.902-5.842-5.543-1.543-1.299-1.554-2.188-1.277-1.416-1.268-1.297-0.785-0.513-0.506-0.303-0.3240.301-0.361-0.145-0.212
EPS -0.33-0.35-0.46-0.55-0.42-0.57-0.58-0.41-0.35-0.37-0.48-0.36-0.4-0.43-0.38-0.28-0.24-0.17-0.12-0.130.26-0.14-0.06-0.074
EPS Diluted -0.33-0.35-0.46-0.55-0.42-0.57-0.58-0.41-0.35-0.37-0.48-0.36-0.4-0.43-0.38-0.28-0.24-0.17-0.12-0.130.26-0.14-0.06-0.074
EBITDA -29.145-30.496-40.016-50.194-38.297-47.706-45.671-31.154-27.224-27.514-35.056-26.291-27.673-28.336-23.883-18.939-17.294-11.055-7.772-7.38114.947-6.59-2.476-2.972
EBITDA Ratio -176.636-52.399-28.121-22.338-2.106-6.03-5.507-1.487-1.299-1.481-2.09-1.219-1.4-1.207-1.209-0.777-0.556-0.513-0.307-0.2890.317-0.317-0.112-0.16